Janux Therapeutics/$JANX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Ticker
$JANX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
91
ISIN
US47103J1051
Website
JANX Metrics
BasicAdvanced
$1.4B
-
-$1.37
3.24
-
Price and volume
Market cap
$1.4B
Beta
3.24
52-week high
$64.87
52-week low
$22.48
Average daily volume
869K
Financial strength
Current ratio
58.47
Quick ratio
58.264
Long term debt to equity
2.054
Total debt to equity
2.233
Profitability
EBITDA (TTM)
-111.536
Gross margin (TTM)
-750.18%
Net profit margin (TTM)
-832.71%
Operating margin (TTM)
-1,216.61%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-8.16%
Return on equity (TTM)
-9.32%
Valuation
Price to revenue (TTM)
141.184
Price to book
1.35
Price to tangible book (TTM)
1.35
Price to free cash flow (TTM)
-28.325
Free cash flow yield (TTM)
-3.53%
Free cash flow per share (TTM)
-81.73%
Growth
Revenue change (TTM)
28.12%
Earnings per share change (TTM)
12.58%
3-year revenue growth (CAGR)
24.43%
3-year earnings per share growth (CAGR)
1.54%
What the Analysts think about JANX
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
Bulls say / Bears say
Leerink Partners initiated coverage of Janux Therapeutics with an 'Outperform' rating and a price target of $79, indicating strong confidence in the company's growth potential. (nasdaq.com)
BTIG Research raised its price target for Janux Therapeutics to $100, reflecting optimism about the company's clinical pipeline and market positioning. (americanbankingnews.com)
Janux Therapeutics reported a 30.99% increase in revenue in 2024 compared to the previous year, demonstrating strong financial growth. (stockanalysis.com)
Janux Therapeutics reported a net loss of $20.2 million for the fourth quarter and $69.0 million for the full year of 2024, indicating ongoing financial challenges. (finviz.com)
The company's increased expenditures, with research and development expenses rising to $20.8 million for the fourth quarter and totaling $68.4 million for the year, may raise concerns about financial sustainability. (finviz.com)
Janux Therapeutics reported zero revenue for the quarter ended March 31, 2025, which may raise concerns about its current revenue generation capabilities. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
JANX Financial Performance
Revenues and expenses
JANX Earnings Performance
Company profitability
JANX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Janux Therapeutics stock?
Janux Therapeutics (JANX) has a market cap of $1.4B as of June 30, 2025.
What is the P/E ratio for Janux Therapeutics stock?
The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of June 30, 2025.
Does Janux Therapeutics stock pay dividends?
No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Janux Therapeutics dividend payment date?
Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Janux Therapeutics?
Janux Therapeutics (JANX) has a beta rating of 3.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.